82998-57-0 Usage
Uses
Used in Pharmaceutical Industry:
3-Iodo-4-methylbenzoic acid is used as a chemical intermediate for the synthesis of unlabeled N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGIMB) and its boc-protected derivative (Boc-SGMIB). These compounds are utilized in the development of pharmaceutical agents, particularly in the field of medicinal chemistry, where they can be further modified or incorporated into drug candidates to target specific biological pathways or receptors.
In the synthesis of SGIMB and Boc-SGMIB, 3-Iodo-4-methylbenzoic acid plays a crucial role in providing the necessary structural features that enable the formation of these compounds. The presence of the iodine atom and the methyl group on the benzene ring allows for the attachment of functional groups, such as the guanidinomethyl group in SGIMB, which can be further protected with a boc group to yield Boc-SGMIB.
The applications of 3-Iodo-4-methylbenzoic acid in the pharmaceutical industry are diverse, as it can be used to create a wide range of drug candidates with different therapeutic properties. By modifying the structure of SGIMB and Boc-SGMIB, researchers can explore their potential as treatments for various diseases and conditions, including cancer, inflammatory disorders, and neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 82998-57-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,9,9 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 82998-57:
(7*8)+(6*2)+(5*9)+(4*9)+(3*8)+(2*5)+(1*7)=190
190 % 10 = 0
So 82998-57-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H7IO2/c1-5-2-3-6(8(10)11)4-7(5)9/h2-4H,1H3,(H,10,11)/p-1
82998-57-0Relevant articles and documents
COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 196, (2011/10/05)
The disclosure provides ten specific compounds with a basic structure of pyrazolo [1, 5-a] pyridine, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 197, (2010/04/06)
The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists
Worm, Karin,Weaver, Damian G.,Green, Rosalyn C.,Saeui, Christopher T.,Dulay, Doreen-Marie S.,Barker, William M.,Cassel, Joel A.,Stabley, Gabriel J.,DeHaven, Robert N.,LaBuda, Christopher J.,Koblish, Michael,Brogdon, Bernice L.,Smith, Steven A.,Dolle, Roland E.
scheme or table, p. 5004 - 5008 (2010/03/24)
Recently sulfamoyl benzamides were identified as a novel series of cannabinoid receptor ligands. Replacing the sulfonamide functionality and reversing the original carboxamide bond led to the discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Selective CB2 agonist 31 (Ki = 2.7; CB1/CB2 = 190) displayed robust activity in a rodent model of postoperative pain.
